# STARTRK-NG (NCT02650401)

> Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02650401
- Phase: PHASE1, PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Hoffmann-La Roche
- Conditions: Solid Tumors; CNS Tumors
- Interventions: Entrectinib
- Enrollment: 69
- Primary outcome: Maximum Tolerated Dose (MTD)
- Primary outcome: Recommended Phase 2 Dose (RP2D) of F1 Formulation In Pediatric Participants Able To Swallow Intact Capsules
- Primary outcome: Recommended Phase 2 Dose (RP2D) of F06 Formulation In Pediatric Participants Able To Swallow Intact Capsules
- Primary outcome: Recommended Phase 2 Dose (RP2D) of F06 Formulation In Pediatric In Participants Dosed Via Feeding Tube (Nasogastric Tube Or Gastric Tube)
- Primary outcome: Recommended Phase 2 Dose (RP2D) Of Minitablets/F15 Formulation In Pediatric Participants Unable To Swallow Intact Capsules
- Primary outcome: Cohort B: Objective Response Rate (ORR)
- Primary outcome: Cohort D: ORR

## Indexed commentary on STARTRK-NG so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=startrk-ng-nct02650401